Aligos Therapeutics (ALGS) Net Margin (2021 - 2025)
Aligos Therapeutics filings provide 5 years of Net Margin readings, the most recent being 11763.91% for Q4 2025.
- On a quarterly basis, Net Margin fell 927451.0% to 11763.91% in Q4 2025 year-over-year; TTM through Dec 2025 was 1106.72%, a 97434.0% increase, with the full-year FY2025 number at 1106.72%, up 252692.0% from a year prior.
- Net Margin hit 11763.91% in Q4 2025 for Aligos Therapeutics, down from 4256.01% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 13854.66% in Q1 2025 to a low of 16396.43% in Q1 2023.
- Median Net Margin over the past 5 years was 1786.9% (2021), compared with a mean of 2799.49%.
- Biggest five-year swings in Net Margin: tumbled -1501117bps in 2023 and later surged 1887815bps in 2025.
- Aligos Therapeutics' Net Margin stood at 10276.29% in 2021, then soared by 98bps to 157.37% in 2022, then tumbled by -782bps to 1388.35% in 2023, then crashed by -79bps to 2489.39% in 2024, then plummeted by -373bps to 11763.91% in 2025.
- The last three reported values for Net Margin were 11763.91% (Q4 2025), 4256.01% (Q3 2025), and 1643.83% (Q2 2025) per Business Quant data.